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Abstract
Prescription opioid misuse and addiction among chronic pain patients are emerging public health
concerns of considerable significance. Estimates suggest that more than 10% of chronic pain
patients misuse opioid analgesics, and the number of fatalities related to nonmedical or
inappropriate use of prescription opioids is climbing. Because the prevalence and adverse
consequences of this threat are increasing, there is a pressing need for research that identifies the
biobehavioral risk chain linking chronic pain, opioid analgesia, and addictive behaviors. To that
end, the current manuscript draws upon current neuropsychopharmacologic research to provide a
conceptual framework of the downward spiral leading to prescription opioid misuse and addiction
among chronic pain patients receiving opioid analgesic pharmacotherapy. Addictive use of opioids
is described as the outcome of a cycle initiated by chronic pain and negative affect and reinforced
by opioidergic-dopamingeric interactions, leading to attentional hypervigilance for pain and drug
cues, dysfunctional connectivity between self-referential and cognitive control networks in the
brain, and allostatic dysregulation of stress and reward circuitry. Implications for clinical practice
are discussed; multimodal, mindfulness-oriented treatment is introduced as a potentially effective
approach to disrupting the downward spiral and facilitating recovery from chronic pain and opioid
addiction.
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1.1. The scope of chronic pain and prescription opioid misuse
Misuse of prescription opioid analgesics is an emerging public health concern that confers
significant risks for overdose, unsafe drug interactions, and the full panoply of adverse
social, legal, and adaptive consequences associated with dependence on any psychoactive
drug. Though the prevalence of prescription opioid misuse across the general U.S.
population has increased more than threefold over the past two decades (Hall et al., 2008), it
is presently unclear to what extent this explosion in prevalence reflects an increase in opioid
misuse by persons without a prescription for opioids versus an increase in nonmedical use of
opioids by persons prescribed opioids for analgesia. This distinction notwithstanding,
nationally-representative surveys indicate that prescription opioid misuse is endemic among
U.S. adolescents and adults; prescription opioids are now among the most commonly
misused drugs in the U.S. (Wilson, 2007). For instance, results of the National Survey on
Drug Use and Health (NSDUH) for 18-to-25 year-olds revealed that 23.8%, 11.1%, and
4.8% reported lifetime, past year, and past month misuse of prescription “pain killers”
(Substance Abuse and Mental Health Services Administration, 2011). NSDUH findings
further indicated that rates of initiation of nonmedical pain reliever use were second only to
those of marijuana, with more than two million persons initiating nonmedical use of opioid
analgesics annually. These findings underscore the pervasive availability and misuse of
these agents in the U.S. The ready accessibility, prevalent misuse, and euphorigenic effects
of prescription opioids would seem to create conditions for widespread dependence on these
agents (Mendelson, Flower, Pletcher, & Galloway, 2008). Recent research does, in fact,
suggest that rates of publically-funded chemical dependency treatment and emergency
department care for prescription opioid use have increased dramatically in recent years and
it is estimated that well over a million Americans are currently dependent on prescription
opioids (Manubay, Muchow, & Sullivan, 2011; Mendelson et al., 2008). As previously
underscored, these statistics do not clearly differentiate opioid misusers with and without
chronic pain; yet, this is a critically important distinction with serious clinical ramifications.
1.2. Diagnostic classification of opioid use patterns
The issue of prescription opioid misuse is further complicated by the diversity of nosological
categories used to classify opioid use patterns and their biopsychosocial consequences. As
defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV), prescription opioid abuse involves a maladaptive pattern of repeated opioid use that:
results in failure to fulfill social, occupational, academic, or familial obligations; continues
despite recurrent legal problems related to opioid use; persists in spite of interpersonal
problems caused or exacerbated by opioids; and occurs in physically hazardous contexts. In
contrast, DSM-IV defines prescription opioid dependence as involving physical symptoms
of dependence, including tolerance and withdrawal, as well as behavioral symptoms
including: taking higher doses than intended; an inability to reduce or stop taking opioids;
spending substantial amounts of time using, obtaining, recovering, or thinking about
opioids; and continued use in spite of adverse physical or psychological consequences
(Zacny et al., 2003). However, some clinicians believe these behavioral criteria for abuse
and dependence are inappropriate for opioid-using chronic pain patients, because patients
who take opioids as prescribed may be unable to reduce their opioid use or may continue
opioid use despite adverse health consequences due to the intractability of their chronic pain.
Instead, many pain and addiction specialists use the American Pain Society (2002) criteria to
identify prescription opioid addiction among chronic pain patients, including symptoms of
impaired control over opioid use, compulsive opioid use, continued use despite harm, and
craving for opioids (Sullivan et al., 2008; Wilson, 2007). Addictive tendencies among
prescription opioid users may be presaged by the presence of opioid misuse behaviors such
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as selling medication or injecting oral formulas (Ives et al., 2006; Sullivan et al., 2008),
although less serious forms of opioid misuse like unauthorized dose escalation are relatively
common among undertreated chronic pain patients and may not indicate opioid addiction.
The presence of more serious misuse behaviors may mark the transition from sanctioned use
of opioids to development of opioid use disorders and addiction (Butler et al., 2007).
1.3. Epidemiology of prescription opioid misuse
Parsing apart these conditions, structured psychiatric interviews conducted for the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) study of more than
43,000 U.S. adults identified 4.7% of respondents as lifetime prescription opioid misusers;
whereas 1.4% of respondents met criteria for a DSM-IV prescription opioid use disorder
(opioid abuse or dependence; Huang et al., 2006). Men, adults with Axis I and Axis II DSM-
IV diagnoses, respondents residing in the West, and young or middle aged adults were at
greatest risk for prescription drug misuse and a prescription opioid use disorder. Other
studies have identified a history of alcohol or illicit drug misuse, anxiety, depression, and
chronic pain as significant risk factors for prescription opioid misuse and dependence
(Amari, Rehm, Goldner, & Fischer, 2011; Pohl & Smith, 2012; Turk, Swanson, & Gatchel,
2008). Individuals suffering from chronic pain disorders, who are at risk for becoming
physically dependent on opioid analgesics when adhering to their prescribed medication
regimen, may be particularly vulnerable to prescription opioid misuse (Butler et al., 2007;
Ives et al., 2006; Sullivan et al., 2010).
Though the prevalence of prescription opioid misuse and addiction among chronic pain
patients has yet to be firmly established by nationally-representative, population-level
surveys, chronic pain itself is highly prevalent in modern society; a meta-analysis of 13
studies reported a weighted mean prevalence of 35.5% for chronic pain of any kind and a
weighted mean prevalence of 11% for severe chronic pain (Ospina & Harstall, 2002). Many
patients with chronic pain have serious medical conditions that require long-term opioid
pharmacotherapy, and a subset of these individuals are at significant risk for escalating from
appropriate opioid use to misuse and finally to opioid addiction. The best available
prevalence estimates for opioid misuse and addiction among chronic pain patients may be
derived from research by Fishbain and colleagues (2007), who reviewed 67
methodologically rigorous studies including thousands of chronic pain patients and
concluded that 3.3%, 11.5%, and 14.5% of these patients, in toto, became addicted to
prescription opioids, engaged in opioid misuse behaviors such as unauthorized dose
escalation and drug hoarding, and used illicit drugs, respectively. Thus, while prescription
opioid addiction among chronic pain patients appears to be relatively rare, opioid misuse in
this population is more common. Although relatively few studies have prospectively
examined factors related to increased risk for prescription drug misuse among chronic pain
patients receiving ongoing opioid pharmacotherapy, recent reports suggest that greater
baseline pain intensity (Edwards et al., 2011; Jamison, Link, & Marceau, 2009),
psychological distress and behavioral problems (Jamison, Butler, Budman, Edwards, &
Wasan, 2010), and status as a cigarette smoker (Novy et al., 2012) predict greater risk for
transitions to prescription opioid misuse, abuse and addiction. There is a pressing need for
additional studies to better understand the risk factors for progression to opioid misuse and
opioid use disorders among chronic pain patients receiving prescription opioid
pharmacotherapy (Larance, Degenhardt, Lintzeris, Winstock, & Mattick, 2011). Further,
novel conceptual frameworks are needed to delineate the biobehavioral risk chain linking
pain, opioid analgesia, opioid misuse, and addiction.
The purpose of this paper is to describe how the neuropharmacologic properties of
prescription opioids interact with cognitive, affective, and physiological factors implicated
in chronic pain and addictive behavior. We first review the neurobiology of opioid agents
Garland et al. Page 3













and pain processing in the human nervous system. Next, we present a conceptual model to
describe how chronic pain, affective dysregulation, and opioid use interact to potentiate each
other and foster opioid addiction. Lastly, we discuss clinical implications of the model for
psychological treatment of chronic pain patients and for the prevention of opioid misuse in
these populations.
2. Neuropharmacologic Effects of Acute Opioid Administration on Central
Nervous System Function
2.1. Effects of opioids on neurotransmission
Opioidergic neurotransmission is necessary for the biologic integrity of the human nervous
system. Both opioid medication and endogenous opioids (those naturally produced by the
body such as beta-endorphin and enkephalins) interact with mu, kappa and delta opioid
receptor-proteins on neuronal membranes widely distributed throughout the cerebral cortex,
thalamus, hypothalamus, periaqueductal grey, interpeduncular median raphe nuclei, and
spinal cord (Arvidsson et al., 1995; Lewis, Pert, Pert, & Herkenham, 1983; Mathieu-Kia,
Fan, Kreek, Simon, & Hiller, 2001; Pan & Pasternak, 2011; Traynor & Wood, 1987). While
mu receptor activation mediates the analgesic properties of selective mu opioid agonists like
morphine, codeine, heroin, meperidine, methadone, and hydromorphone (Becker, Gandhi, &
Schweinhardt, 2012; Fields, 2011; Julien, 2007), the abuse liability of prescription opiate
medications is thought to be due to the interactive effects of mu receptor activation on
dopaminergic transmission. Acute administration of mu receptor agonists indirectly excites
dopamine-secreting neurons in the ventral tegmental area via GABAergic mechanisms
(Chiara & North, 1992; Johnson & North, 1992). Indirect action of opioids on dopamine
neurotransmission appears to be integral to the reinforcing and rewarding properties of
opioids, as well as opioid addiction (Berridge, Robinson, & Aldridge, 2009; Le Merrer,
Becker, Befort, & Kieffer, 2009; Volkow, Wang, Fowler, Tomasi, & Telang, 2011).
2.2. Effects of opioids on neurocognition
Functional magnetic resonance imaging (fMRI) has provided insight into the effects of
opioid administration on human brain function. Single-dose opioid administration to
opioidnaïve, healthy individuals activates brain regions involved in processing reward
(nucleus accumbens, extended amygdala, orbitalfrontal gyrus, and hippocampus) (Becerra,
Harter, Gonzalez, & Borsook, 2006; Wanigasekera et al., 2012), while decreasing brain
activation in brain regions involved in cognitive control and attention (dorsolateral
prefrontal cortex, anterior cingulate cortex, inferior parietal lobe) (Becerra et al., 2006;
Jastrzab, Mackey, Chu, Stringer, & Younger, 2012; Lee, Wanigasekera, & Tracey, 2012).
Opioid-induced hyperactivation of limbic circuitry is similar to that elicited by
psychostimulants (Breiter et al., 1997), whereas opioid-induced cortical inhibition is
comparable to that elicited by sedative or anesthetic drugs (Fiset, Plourde, & Backman,
2005). Acute administration of higher concentrations of opioids reduces neural activity in
the brain stem and medial thalamic nuclei, which can lead to diminished sensory, motor, and
cognitive functioning to the point of unconsciousness (Becerra et al., 2006). Other
neuroimaging research, involving single-dose opioid administration in the absence of pain to
healthy individuals, revealed activations in orbitofrontal cortex, anterior cingulate cortex,
insula, and amygdala that were associated with the time course of subjective reports of
dizziness, drowsiness, and euphoria (Leppä et al., 2006). Consistent with prevailing models
of drug addiction, these findings suggest that high-risk individuals may start along the path
of addiction to prescription opioids after experiencing an initial and transient hyperactivation
of reward circuitry coupled with disruption in neural circuitry subserving cognitive function.
Garland et al. Page 4













Disrupted cognitive control neural circuitry function is evident in a host of studies indicating
cognitive and psychomotor impairments such as decrements in working memory, reduced
cognitive flexibility, and increased impulsivity in long-term opioid users (Baldacchino,
Balfour, Passetti, Humphris, & Matthews, 2012; Mintzer, Copersino, & Stitzer, 2005;
Prosser, London, & Galynker, 2009; Verdejo, Toribio, Orozco, Puente, & Pérez-García,
2005; Zacny, 1995) and healthy, opioid-naïve individuals (Baldacchino, Balfour, Passetti,
Humphris, & Matthews, 2012; Cherrier, Amory, Ersek, Risler, & Shen, 2009; Schneider et
al., 1999; Walker & Zacny, 1999; Zacny, 1995). Deactivation in brain regions involved in
executive function (e.g., anterior cingulate cortex, dorsolateral prefrontal cortex) following
acute, single-dose opioid administration provides further mechanistic insight into the
relationship between opioid use and cognitive impairment (Becerra et al., 2006; Jastrzab et
al., 2012; Lee et al., 2012; Prosser et al., 2009). Opioid-induced deficits in executive
function, compounded with those associated with chronic pain (Kendall et al., 2010; Tassain
et al., 2003), may compromise the patient’s ability to exert cognitive control needed to cope
through non-pharmacologic means, thereby inadvertently promoting dependence on opioids
as a means of obtaining relief from pain.
3. Pain and the Nociceptive and Affective Dimensions of Opioid-Induced
Analgesia
3.1. Neurophysiology of pain
Pain is a complex, biopsychosocial experience that arises from the interaction between
sensory, cognitive, and affective factors. Acute pain is most often induced by noxious
stimulation, tissue damage, and/or disease and is a beneficial process that helps to preserve
the morphological integrity of the organism. Acute pain is associated with activation in a
widely distributed network of highly connected brain regions including primary and
secondary somatosensory cortices, bilateral insula, thalamus, anterior cingulate cortex, and
the prefrontal cortex (Coghill, McHaffie, & Yen, 2003). Chronic pain on the other hand may
not be clearly linked to an observable physiological or neural pathology. In some cases, the
CNS may generate pain in the absence of input from peripheral or visceral nociceptors, as
evidenced by conditions like phantom limb pain, irritable bowel syndrome, and chronic pain
due to CNS changes secondary to stroke (Loeser & Melzack, 1999; Melzack, 1999; Spiller
et al., 2007). In such cases, the intensity of chronic pain is only weakly or not at all
associated with the degree of actual tissue damage (Waddell, McCulloch, Kummel, &
Venner, 1980; Waddell, 1996). With time, pain may become the output of a pattern of
familiar sensory inputs triggering cognitive and affective reactions that have previously been
tied to the pain experience (Melzack, 1999). In this way, even the anticipation of pain and
suffering may result in somatic discomfort or functional disability of a similar or even
greater magnitude as the actual painful event (Crombez, Vlaeyen, Heuts, & Lysens, 1999).
Chronic pain may be exacerbated by stress, environmental variables, emotional states, and
other psychological factors (Garland, 2012; Loeser & Melzack, 1999; Voscopoulos & Lema,
2010).
3.2. A role for default mode networks in pain processing
Although in some cases chronic pain stems from an initial painful insult to the body, its
progression is associated with the interaction between original injury, CNS, and cognitive-
affective dysregulation (Apkarian, Bushnell, Treede, & Zubieta, 2005). With regard to the
latter factor, recent neuroimaging research has identified a role for self-referential thought
processes in chronic pain (Baliki et al., 2006; Loggia et al., 2012; Wasan et al., 2011). In
healthy individuals, self-referential thought (i.e., thought pertaining to an individual’s
autobiographical narrative or life story) is believed to be reflected by oscillating activity in a
distinct network of brain regions (posterior cingulate cortex/precuneus, medial prefrontal
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cortex, and the inferior and lateral temporal cortices) referred to as the default mode network
(DMN) (Raichle et al., 2001). Recent findings from resting-state functional connectivity
analyses of regional brain signals reveal that chronic pain patients exhibit abnormal
functional connections between the default mode network and the anterior insula (Loggia et
al., 2012), a region crucially involved in evaluating sensory processes. It has been postulated
that the experience of chronic pain is related to abnormal default mode processes where pain
experience becomes the primary object of self-referential thought (Zeidan & Coghill, 2012).
Dysregulated DMN connectivity may underpin the development of the entrapped sense of
identity and autobiographical narrative dominated by pain-related memories and
associations so common to chronic pain patients (Hellström, 2001; Morley, Davies, &
Barton, 2005; Pincus & Morley, 2001). The relationship between DMN and chronic pain is
also supported by findings demonstrating the role of the perigenual anterior cingulate cortex,
a brain region involved in mediating the cognitive modulation of pain (Vogt, 2005). Recent
findings reveal that chronic pain patient’s self-report of pain is negatively associated with
connectivity between the perigenual anterior cingulate cortex and the DMN (Loggia et al.,
2012; Wasan et al., 2011). That is, those who report more intense chronic pain exhibit
decreased connectivity between the perigenual anterior cingulate and the DMN, likely
reflecting reduced ability to govern pain-related thought processes. Conversely, increased
functional connectivity between anterior cingulate and DMN regions may reflect a process
for attenuating pain.
3.3. Descending nociceptive inhibition and opioid analgesia
Thus, the brain does not passively receive nociceptive information from the body, but
instead actively regulates nociception by way of interactions between descending pain
modulatory system (Heinricher, Tavares, Leith, & Lumb, 2009; Melzack & Wall, 1965;
Reynolds, 1969) and cortico-cortical networks (Rainville, 2002). The descending pain
modulatory system exerts influences on nociceptive input from the spinal cord through a
network of cortical, subcortical, and brainstem structures including prefrontal cortex,
anterior cingulate cortex, insula, amygdala, hypothalamus, periaqueductal grey, rostral
ventromedial medulla, and dorsolateral pons (Tracey & Mantyh, 2007). The descending pain
modulatory system has been construed as the means by which the CNS inhibits nociceptive
signals at the spinal outputs (Heinricher et al., 2009). Endogenous and exogenous opioids
relieve pain by targeting the descending pain modulatory system (Besson, 1999), most
notably in the periaqueductal grey, a brain region involved in processing the placebo-
analgesia (Tracey, 2010). In addition, acute, single-dose administration of opioids in healthy
individuals exerts direct analgesic effects by reducing sensory evaluation processes
evidenced by reduced activation in brain regions corresponding to processing lower-level
afferent processes (i.e., primary and secondary somatosensory cortex, thalamus) (Wagner et
al., 2007; Wise et al., 2002), and by modulating neurotransmission in the substantia
gelatinosa of the dorsal horn of the spine (Le Bars, Guilbaud, Chitour, & Besson, 1980;
Yaksh, 1981, 1987). Moreover, in a preclinical animal model, acute opioid administration
elicited dose-dependent modulation of dopaminergic activity in spinal neurons that mediate
nociception (Pappas, Kennedy, Goudreau, & Lookingland, 2011). Among healthy human
volunteers, increasing concentrations of opioids across a single, experimental session
monotonically decreased sensory processing in primary and secondary somatosensory cortex
and the posterior insula, while dramatically attenuating pain processing in brain regions that
mediate affective dimension of pain like the amygdala (Oertel et al., 2007).
Given the complexity of pain, it is perhaps not surprising that opioid analgesia operates
through both neuropharmacologic and psychological mechanisms. In addition to attenuating
sensory aspects of pain (i.e., nociception), opioids may alleviate the affective dimensions of
pain (e.g., suffering). In that regard, among healthy individuals, analgesia induced through
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acute opioid administration operates, in part, through modulating activation of the anterior
and posterior cingulate cortex (Wagner et al., 2007), anterior insula (Oertel et al., 2007), and
the hypothalamus (Becerra et al., 2006), key nodes in the central autonomic network, a
series of neural circuits that regulate attention, emotion, and neurovisceral integration
(Thayer & Lane, 2009). Opioids, like all drugs of addiction, also stimulate mesolimbic
dopamine reward systems (Chiara & North, 1992; Johnson & North, 1992). Opioid-induced
dopamine release in the nucleus accumbens associated with positive mood and reward may
confer therapeutic benefit for pain management (Center, 2011). Indeed, pleasure and pain
have mutually inhibitory effects through complex opioid-dopamine interactions in cortico-
limbic-striatal circuitry (Leknes & Tracey, 2008). Through these and other neural targets,
opioids change the attentional and affective response to nociceptive information, and in so
doing, temper the emotional averseness and unpleasantness of pain (Dellemijn & Vanneste,
1997). To be clear, much of what is known about the psychobiological mechanisms of
opioid-induced analgesia comes from studies of healthy individuals exposed to laboratory
pain inductions. Yet, the development of co-occurring chronic pain and opioid use disorders
over time may alter the neurobiological response to opioids in clinically significant ways, as
detailed below.
4. Neurobiological transitions from opioid use to dependence and addiction
4.1. The neurobiological progression from opioid use to dependence
Opioid therapy for chronic pain often provides effective analgesia but confers significant
risk for the development of opioid use disorders in a subset of vulnerable individuals
(Denisco et al., 2008; Passik, 2009), as described earlier in the introduction of this paper.
Prolonged, medically-appropriate opioid use produces physical dependence symptoms via
neuroadaptations resulting in tolerance to opioids, withdrawal when opioids are
discontinued, and, in some instances, opioid-induced hyperalgesia (Chu, Angst, & Clark,
2008). These physical symptoms of opioid dependence are natural responses to extended use
of opioids, and do not signal the presence of an opioid use disorder. Thus, there is a
difference between physiological dependence on opioids and the pathology of addiction
(Shurman, Koob, & Gutstein, 2010). Addiction arises from a usurpation of normal reward
learning mechanisms caused by repeated pharmacologic interruption to normal brain
function, resulting in neuroadaptations and fundamental alterations to brain structure. Such
neuroplastic changes commence with early use of opioids as associations are forged between
drug-related stimuli and reward responses (i.e., transient neuroplasticity), and may eventuate
in compulsive, addictive habits as these neurobiological changes become entrenched (i.e.,
stable neuroplasticity) (Kalivas & O’Brien, 2008).
Opioid-induced durable changes in brain structure and function referred to as
neuroplasticity, like the neuroadaptations stimulated by other drugs of addiction, may stem
from a cascade of neurobiological events governed by dopaminergic activity in cortico-
limbic-striatal circuits (Kalivas & O’Brien, 2008). Acute administration of opioids results in
dopamine release from the ventral tegmental area to the prefrontal cortex and nucleus
accumbens (Center, 2011; Shippenberg, Bals-Kubik, & Herz, 1993). This dopamingerically-
mediated process facilitates the learning of drug reward; when opioids result in pain relief,
this signals the reward value of opioid-related stimuli (Becker et al., 2012), increasing their
incentive salience (Robinson & Berridge, 2008). In other words, the individual learns that
opioids and opioid-related cues (e.g., the sight of a pill bottle, a prescription slip, or even the
pharmacy where the opioids are dispensed) are motivationally salient, and should be sought
after as a means of maintaining a positive hedonic tone. As chronic pain patients engage in
recurrent opioid use or misuse, opioid cues may become salient through the pharmacologic
reward induced by opioid consumption (positive reinforcement), as well as through the
analgesic effects of the drug that remove or allay the aversive experience of pain (negative
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reinforcement) (Fields, 2004). The incentive salience of opioid cues may increase over time
as opioid dependence is established via the process of sensitization of the mesolimbic
dopamine system (Robinson & Berridge, 2008). Such reward learning may be coupled with
a strong drive towards opioids or a “wanting” that is independent of any “liking” or
conscious preference for the drug (Berridge et al., 2009). In fact, many chronic pain patients
express a strong dislike of opioids due to their side effects or the stigma associated with
opioid use, yet the compulsion to take opioids increases despite this sentiment of disdain.
4.2. Establishment of opioid misuse habits
Over time, this transient neuroplasticity becomes more stable as individuals begin to form
unconscious appetitive habits, mediated by structural and functional changes in cortico-
limbic-striatal circuits (Yin & Knowlton, 2006). Modified striatal circuitry may govern the
implicit neurocognitive operations that direct and impel addictive behaviors and craving
states characteristic of disordered forms of substance use, including prescription opioid use
disorders, (Stacy & Wiers, 2010). Repeated substance use is thought to establish automatic
drug-use action schemas (i.e., memory systems that compel and coordinate consumption of
the substance through automatized sequences of stimulus-bound, context-dependent
behavior, including the biasing of attention towards substance-relevant stimuli) (Garland,
Boettiger, & Howard, 2011; Pierce & Vanderschuren, 2010; Tiffany, 1990). Insofar as cues
associated with past drug use are motivationally salient for habitual drug users, they are able
to consequently capture attention, which in turn amplifies their motivational salience
(Franken, 2003). This phenomenon, known as addiction attentional bias, is associated with
craving (Field, Munafo, & Franken, 2009), increases drug use (Field & Eastwood, 2005),
and predicts relapse (Garland, Franken, & Howard, 2011) among persons with alcohol and
illicit drug dependence. A recent study from our laboratory demonstrated that chronic pain
patients who met diagnostic criteria for opioid dependence exhibited a significant attentional
bias towards prescription opioid cues (e.g., photographs of a pills or pill bottles) (Garland,
Froeliger, Passik, & Howard, 2012). Moreover, opioid attentional bias was positively
correlated with opioid craving. When external (e.g., the sight of a pill bottle) or internal
(e.g., pain, stress) cues associated with past opioid use capture attention, they may trigger
dopamine release and activate habitual drug use routines subserved by neuroplastic
alterations to cortico-limbic-striatal circuits (Everitt & Robbins, 2005; Kalivas & Volkow,
2005).
4.3. Dysregulation of reward processing and default mode activity in opioid addiction
As addictive automaticity is entrenched, neural circuits mediating associations between drug
cues and learned appetitive responses become strengthened, while non-drug-related learning
is diminished (Hyman, 2005; Kalivas & O’Brien, 2008; Kalivas & Volkow, 2005). Thus,
recurrent opioid use may lead to insensitivity in the dopamine system toward natural
rewards, like food, sex, or social affiliation (Volkow et al., 2011). Indeed, decreased
responsiveness to natural reinforcers has been observed among opiate dependent individuals
(Lubman, Allen, Peters, & Deakin, 2008) and is robustly predictive of future opiate
consumption (Lubman et al., 2009). Thus, the addictive cycle becomes more and more
insidious as both the pain threshold and the ability to experience natural pleasure decreases.
Indeed, increased sensitization to pain, when coupled with tolerance to the analgesic effects
of opioids, can result in increased opioid craving (Ren, Shi, Epstein, Wang, & Lu, 2009) and
consumption (Martell et al., 2007). Furthermore, pain itself may decrease responsiveness to
natural rewards, resulting in blunted dopaminergic responses to naturally-rewarding stimuli
and anhedonia (Becker et al., 2012; Leknes & Tracey, 2008). As a result of increasing
hyperalgesia and anhedonia, the normative affective balance is tipped towards negativity,
further propelling the downward spiral of pain and opioid addiction.
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This downward spiral may also crucially involve maladaptive patterns of self-referential
thought and aberrant default mode processes as the healthy sense of identity transmogrifies
into a self-concept entrapped by pain and entangled with dependence on opioid analgesia.
Recent findings provide evidence for dysfunctional default mode-related neural function in
opiate addicts, characterized by strong functional connectivity between the nucleus
accumbens and prefrontal cortex coupled with attenuated functional connectivity between
the prefrontal cortex and anterior cingulate cortex (Ma et al., 2010), a brain structure whose
cognitive control functions are significantly impaired in opiate addicts (Yücel et al., 2007).
Similarly, chronic pain patients reporting greater pain exhibit decreased connectivity
between the default mode network and the anterior cingulate cortex (Loggia et al., in press).
Speculatively, similar changes in self-referential, executive, and reward circuitry might
underlie the transition from opioid use to misuse and addiction, as the patient’s sense of self
and autobiographical narrative becomes more entrenched in the downward spiral of seeking
relief from pain through opioids. It is likely that interactions between sensory, cognitive, and
self-referential processes fuel the progression toward addictive use of opioids among chronic
pain patients.
5. Pain, Negative Emotion, and Opioid Addiction
5.1. Emotional modulation of pain
The aversive nature of pain elicits a powerful emotional reaction that feeds back to modulate
pain perception. Pain is often accompanied by feelings of anger, sadness and fear depending
on how the pain is cognitively appraised. Persistent negative evaluations of noxious sensory
events can lead to pain catastrophizing, where the individual interprets uncomfortable or
even innocuous somatic sensations as indicating the presence of a serious or mortal threat
and consequently underestimate their ability to cope with those respective sensations. These
experiences illustrate the importance of cognitive appraisal processes in the construction of
the subjective experience of pain. Catastrophic appraisals are largely mediated by fear and
produce an intensified pain or allodynia which can result in greater functional disability and
reduced quality of life (Crombez et al., 1999; Turner, Jensen, Warms, & Cardenas, 2002).
Brain regions involved in the processing negative affect are also associated with processing
the subjective experience of pain. These areas include executive-level brain regions such as
the anterior cingulate and prefrontal cortex and sensory and self-evaluatory regions such as
the anterior insula (Craig, 2003; Wiech & Tracey, 2009). Thus, when individuals experience
pain-related negative emotions, the heightened neural processing of threat produces a pre-
cognitive mental set that primes the individual for an exacerbated subjective experience of
pain (De Wied & Verbaten, 2001; Kirwilliam & Derbyshire, 2008; Ploner, Lee, Wiech,
Bingel, & Tracey, 2010) and subsequently increases the likelihood that innocuous somatic
sensations will be interpreted as painful (Bogaerts, Janssens, De Peuter, Van Diest, & Van
den Bergh, 2009; Panerai, 2011; Strigo, Simmons, Matthews, Craig, & Paulus, 2008).
The fear of pain, a clinical feature of chronic pain patients, is associated with hypervigilance
for and sustained attention to pain-related stimuli (Haggman, Sharpe, Nicholas, &
Refshauge, 2010; Keogh, Ellery, Hunt, & Hannent, 2001). Thus, negative affect biases
attention toward pain, which then increases its aversive quality. Activation of the neural
circuitry subserving negative affect, stress and pain disrupts the function of brain circuits
that govern cognitive control (i.e., circuits governed by regions of prefrontal cortex), which
may reduce the ability to regulate pain using higher-order cognitive coping strategies like
reappraisal or viewing the pain as controllable (Arnsten, 2009; Lawrence, Hoeft, Sheau, &
Mackey, 2011). Furthermore, stress and negative affect intensify sympathetic nervous
system activity associated with pain, manifested in increased anxiety, heart rate, skin
conductance responses, and muscle tension that is perceived as painful muscle spasms (Flor,
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Turk, & Birbaumer, 1985; Lundberg et al., 1999; Tousignant-Laflamme & Marchand,
2006). Thus, negative affective states may result from chronic pain and feed back into
biobehavioral processes that amplify pain perception (Loggia et al., 2012; Ploner et al.,
2010) and exacerbate suffering. Concomitantly, negative affect predicts increased opioid
craving among long-term opioid users (Wasan et al., 2012) and is associated with initiation
and continued misuse of prescribed opioids (Sullivan, Edlund, Zhang, Unutzer, & Wells,
2006). Opioid misusers may use opioids to self-medicate (Khantzian, 1997) the negative
affective states and autonomic arousal that cause, co-occur with, or result from pain (Jänig
& Habler, 2000; Martenson, Cetas, & Heinricher, 2009). In turn, self-medication of negative
emotions with opioids may promote the development of opioid addiction.
5.2. Allostasis and the downward spiral of chronic pain and opioid addiction
Negative emotions may contribute to the development of addiction through the progressive
dysregulation of stress and reward circuitry in the extended amygdala and altered
neurotransmitter function characterized by increased recruitment of other brain arousal-
stress systems (Koob & Le Moal, 2008; Koob, 2009; R. J. Smith & Aston-Jones, 2008).
These systems are thought to mediate not only stress but also antireward - that is, a
homeostatic process whereby brain systems maintain reward within a given limit or set point
(Koob & Le Moal, 1997, 2001, 2008). According to Koob and LeMoal’s allostatic model of
addiction (1997, 2001), use of substances to compensate for dysphoria results in an
opponent process that leads to neurobiological sensitization in the extended amygdala and
the brain arousal-stress systems to threat and harm, while sensitivity to reward is decreased.
Thus, in addiction, homeostasis is broken, leading to a chronic deviation of brain systems
from their normal operating level, termed allostasis. This shift in reward threshold, induced
by activation of brain antireward systems may then elicit increased consumption of
psychoactive substances as a means of achieving a hedonic equilibrium. Ironically, this
attempt to reach a hedonic state comes with a cost: the continued use of substances further
increases the reward set point in the brain, making the individual increasingly insensitive to
naturally-rewarding experiences while becoming increasingly sensitive to punishment, pain,
and other aversive states (Koob & Le Moal, 2008). Thus, load incurred from prior injury and
enhanced by the pharmacological effects of psychoactive substances promotes
neuroadaptation to drug effects, modulates sensitization to rewards and punishment, and
intensifies negative mood states and pain. Thus, in addition to hyperalgesia, prolonged
misuse of opioids to medicate negative affective states and induce euphoria may result in
hyperkatifeia, an increased sensitivity to emotional distress (Shurman et al., 2010). This
cyclic process then elicits further substance use as a means of countering dysphoric mood
(see Figure 1). Recurrent use of opioids to maintain positive emotional functioning in the
face of stress and pain may result in a shift in the hedonic set point of the brain such that the
individual becomes increasingly dependent on opioids to maintain a sense of psychological
well-being. In turn, the sense of self may become more entangled with narratives of pain and
opioid use.
As the cycle spirals further downward, the experience of pain may cue habitual drug use
routines, even when they have been rendered ineffectual due to increased tolerance to opioid
analgesia. Although chronic use of opioids may produce limited analgesic effects, once the
habit of opioid misuse has been established, it may continue despite countervailing health,
social, and legal reasons to adhere to the prescribed medication regimen. Thus, pain comes
to trigger the automatic reaction (i.e. taking medication at higher than prescribed doses), and
the conscious decision to take the medication is no longer the dominant factor in opioid use.
Unconscious habits replace conscious consideration and deliberate evaluation of the level of
pain as the primary determinate of opioid dosing. Addictive opioid use may capitalize on
non-drug striatal habit mechanisms, which, once established, operate in the absence of
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pharmacologic reward or drug-induced disruption of normal control (Graybiel, 2008). In
other words, whether or not opioid use works to relieve pain (or even produces
hyperalgesia), it may persist as an ingrained habit triggered by sensations of pain and
external drug-related cues which were originally imbued with motivational salience during
the acquisition of the habit of opioid use (Wood & Neal, 2007). This rigid, scripted response
to contextual conditions, known as mindlessness (Langer, 1992), may fuel the downward
spiral of chronic pain, suffering, and opioid addiction.
When access to opioids is restricted despite the presence of pain and addictive cues, opioid
dependent individuals may experience an intensely aversive craving state, characterized by
dysphoria, anxiety, and craving coupled with somatic symptoms of withdrawal that drives
an obsessive or intrusive preoccupation with obtaining opioids (Shurman et al., 2010). These
experiences promote addictive use of opioids as dependent individuals may feel impelled to
avoid the discomfort, dysphoria and psychic distress that accompany withdrawal.
Compulsive consumption of opioids to satisfy craving and allay withdrawal irrespective of
the presence of actual injury or tissue damage may be seen as a hallmark of addiction among
pain patients.
6. Clinical Implications
In light of the complex, insidious processes outlined in this paper, multimodal interventions
are needed to target the manifold links in the risk chain between chronic pain and
prescription opioid addiction. Novel therapies that can facilitate attentional regulation of
opioid cue-reactivity and enhance positive emotion while ameliorating pain may be
efficacious means of addressing this pernicious and prevalent social problem. In that regard,
mindfulness-based therapies, which are held to strengthen attentional control and temper
emotional reactivity (Hölzel et al., 2011; Vago & Silbersweig, 2013), may be especially
promising.
We hypothesize that mindfulness training may interrupt the downward spiral linking pain to
addictive use of opioids in the following ways. Moving down the spiral (see Figure 1) from
top to bottom, mindfulness training may first reduce the severity and unpleasantness of
chronic pain (Chiesa & Serretti, 2011; Gaylord et al., 2011; Rosenzweig et al., 2010; Zeidan
et al., 2011) by attenuating emotionally-aversive appraisals of pain sensations and
decreasing pain sensitivity (Garland, Gaylord, et al., 2011; Zeidan, Grant, Brown, McHaffie,
& Coghill, 2012). Second, due to its facilitative effects on attentional re-orienting capacity
(Jha, Krompinger, & Baime, 2007) mindfulness may reduce attentional fixation on and
hypervigilance for pain (Vago & Nakamura, 2012; Garland & Howard, in press). Third,
because mindfulness involves adopting a nonjudgmental stance towards emotional
experience (Hölzel et al., 2011), mindfulness may decrease negative emotional reactivity
(Froeliger, Garland, Modlin, & McClernon, 2012), thereby reducing pain catastrophizing
(Garland, Gaylord, et al., 2011) and preventing the need to self-medicate stress and negative
emotions with opioids. Fourth, mindfulness may lessen addiction attentional bias (Garland,
Boettiger, Gaylord, Chanon, & Howard, 2012; Garland, Gaylord, Boettiger, & Howard,
2010), and, as such, reduce biased processing of prescription opioid-related cues. Fifth,
mindfulness may decrease craving (Bowen et al., 2009) by attenuating bottom-up reactivity
to drug-related stimuli (Westbrook et al., 2011) and decoupling negative affect from the urge
to use substances (Witkiewitz & Bowen, 2011). Sixth, mindfulness may enhance positive
affect and hedonic processing (Geschwind, Peeters, Drukker, Van Os, & Wichers, 2011),
undoing the insensitivity to natural reward that fuels increasing dependence on opioids.
Seventh, mindfulness may decrease habit behavior (Wenk-Sormaz, 2005) and reduce rigid
adherence to scripted cognitive responses (Greenberg et al., 2012), resulting in enhanced
cognitive control of compulsive and habitual opioid use. Lastly, mindfulness may aid in
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regulating pain-primed mental states and self-referential processes that have been found to
exacerbate and prolong the subjective experience of chronic pain (Loggia et al., 2012). In
that regard, studies suggest that mindfulness practice is associated with decreased self-
referential activations in cortical midline brain structures (Farb, Segal, Mayberg, Bean,
McKeon, Fatima, & Anderson, 2007), reduced default mode processing (Brewer et al.,
2011) and increased functional connectivity between default mode networks and attentional
networks (Froeliger et al., 2012). Through these therapeutic pathways, mindfulness-based
interventions might help to disrupt and reverse the cycle of maladaptive pain coping habits
and aberrant drug-seeking behaviors that comprise the downward spiral of pain and opioid
addiction.
Though mindfulness-based approaches are relatively novel means of addressing co-
occurring pain and opioid misuse, cognitive-behavioral therapy (CBT) has been used for
more than three decades to treat chronic pain syndromes. As early as 1976 Fordyce
advanced a behavioral model of pain management focused on operant conditioning,
reinforcement of functional behaviors, and progressive relaxation (Fordyce, 1976). Modern
CBT, which combines behavioral techniques with challenging of maladaptive thoughts
contributing to pain catastrophizing and addictive behavior, have been shown to enhance
coping with pain (Morley, Williams, & Hussain, 2008) and reduce substance misuse (Magill
& Ray, 2009). A systematic review and meta-analysis conducted by Williams, Eccleston, &
Morley (2012) indicated that CBT produced small to medium effect size improvements in
pain, disability, and mood .
In addition, research on positive psychology suggests that savoring pleasant experiences can
induce motivation and increase positive emotions (Quoidback, Berry, Hansenne, &
Mikolajczak, 2010), which in turn are associated with decreased pain hypervigilance and
fear of pain (Crombez, Viane, Eccleston, Devulder, & Goubert, 2012). A host of basic
biobehavioral research studies support the presence of positive affect analgesia. In healthy
subjects, presentation of positive affective photographs produced greater pain tolerance on a
cold pressor task than neutral and negative affective photos (de Wied & Verbaten, 2001).
Positive affect analgesia has also been observed following induction of positive affect
through other means including: humorous (Weisenberg, Raz, & Hener, 1998) and romantic
films (Zillman, de Wid, King-Jablonski, Jenzowsky, 1996), laughter (Cogan et al., 1987),
and pleasant music (Silvestrini et al., 2011). Moreover, induction of positive affect through
therapeutic suggestion (Zelman et al., 1991) and guided imagery (Bruehl, Carlson,
McCubbin, 1993) has also been shown to reduce pain. It is unknown to what extent positive
affect analgesia may influence chronic pain.
Multimodal interventions that capitalize on these combined therapeutic approaches might be
especially efficacious. In one of the first, well-controlled studies of a psychological
treatment for chronic pain patients at high risk for misusing opioids, Jamison and colleagues
(2010) conducted a randomized controlled trial of a multimodal intervention that combined
cognitive-behavioral (e.g., coping with urges, problem solving) and motivational elements
(e.g., maintaining abstinence motivations, balancing fleeting versus durable satisfactions) to
decrease prescription opioid misuse and increase medication compliance. Significantly
fewer high-risk individuals randomly assigned to this experimental intervention misused
opioids at a six-month follow-up than those assigned to a standard medical care condition.
Though most were satisfied with the study treatment, less than one-third of participants felt
that it improved their pain.
To address this unmet need, Mindfulness-Oriented Recovery Enhancement (MORE;
Garland, 2013), unites complementary aspects of mindfulness training, CBT, and principles
from positive psychology into an integrative approach to treating co-occurring chronic pain
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and prescription opioid misuse. Recent findings from a randomized controlled trial
demonstrate that MORE led to significant reductions in pain attentional bias coupled with
decreased emotional reactivity and increased perceived control over pain in a sample of
chronic pain patients receiving long-term opioid therapy, many of whom were opioid
misusers (Garland & Howard, in press). New clinical outcome data from this trial suggest
that MORE may significantly reduce pain severity and functional interference while
decreasing opioid misuse and craving (Garland, Manusov, Froeliger, Williams, Kelly,
Mann, & Howard, 2013). Whether mindfulness training or other forms of behavioral
intervention can disrupt the downward spiral of chronic pain and opioid addiction is an open
question to be explored in future clinical research.
7. Conclusion
In summary, we theorize that the problem of co-occurring chronic pain and opioid addiction
involves a cycle of behavioral escalation where nociception and stress trigger hypervigilance
and catastrophizing, amplifying pain and provoking recurrent self-medication with opioids,
which in turn biases attention towards opioid-related cues that come to elicit the habit of
drug use despite ever diminishing analgesia. Uncontrolled use of opioids coupled with
chronic pain dysregulates reward processing in the brain, depriving the individual from
experiencing pleasure from objects and events in the natural environment. As the sense of
self becomes ensnared in pain-laden narratives and entrapped by a compulsive drive for
relief, this downward spiral may result in a loss of control over opioid use and increasing
reliance on opioids to maintain an ever-diminishing sense of well-being.
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Prescription opioid misuse among chronic pain patients is a public health threat.
Cognitive-affective factors interact with the neuropharmacology of opioid analgesia.
Opioid misuse may arise out of dysfunctional brain connectivity and allostasis.
We describe a conceptual model linking chronic pain and addictive opioid use.
Our model has implications for mindfulness-based treatment of these comorbidities.
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The Downward Spiral of Chronic Pain and Opioid Addiction.
In brief, the problem of co-occurring chronic pain and opioid addiction involves a cycle of
behavioral escalation in which nociception triggers pain hypervigilance and catastrophizing,
amplifying pain with emotional anguish. Among affectively dysregulated individuals,
recurrent self-administration of opioids in response to pain and negative emotions results in
associative learning processes that bias attention towards opioid-related cues (e.g., a sight of
a pill bottle), strengthening the automatic habit of opioid use despite tolerance to opioid
analgesia. Chronic pain and prolonged opioid misuse causes allostatic changes to stress and
reward circuitry in the brain, increasing sensitivity to pain and decreasing the pleasure
derived from healthful objects and events. As functional connectivity between the default
mode network and other neural circuits changes over time, the sense of self may become
entwined with pain-laden narratives and entrapped by a compulsive drive for relief. This
downward spiral may ultimately result in mindless, uncontrolled opioid use and addiction.
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